Sort By

Hemolytic-Uremic Syndrome Approved Drugs

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hemolytic-Uremic Syndrome.

Found 2 Approved Drugs for Hemolytic-Uremic Syndrome

Soliris

Generic Name
Eculizumab
Form: Injection
Method of administration: Intravenous
FDA approval date: April 02, 2007
Classification: Complement Inhibitor
Summary: Soliris is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
View Treatment

Ultomiris

Generic Name
Ravulizumab
Form: Solution
Method of administration: Intravenous
FDA approval date: December 21, 2018
Classification: Complement Inhibitor
Summary: ULTOMIRIS is indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH) ( 1 ). the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) ( 1 ). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
View Treatment
Showing 1-2 of 2
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances